Sign inJoin waitlistJoin the waitlist

Amit Mahipal

Co-Lead, Gastrointestinal Disease Program, UH Seidman Cancer Center · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · · ·

History

Hematology and Medical Oncology
Thomas Jefferson University Hospital
2008–2011
Internal Medicine
Univ of Connecticut Health Center/John Dempsey Hospital
2005–2008
University of Minnesota
2003–2005
Maulana Azad Medical College
1999–2003

Research

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012…
Journal of Clinical Oncology · 2016 · 701 citations
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
New England Journal of Medicine · 2023 · 502 citations
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
JAMA Oncology · 2020 · 366 citations

Sakti Chakrabarti
38 papers
Zhaohui Jin
35 papers · 1 as a fellow
ST
Sri Harsha Tella
31 papers · 17 as a fellow
Mitesh Borad
29 papers
Robert McWilliams
25 papers
Tanios Bekaii-Saab
22 papers
AK
Anuhya Kommalapati
21 papers · 21 as a resident
Michael Storandt
20 papers · 20 as a resident
Nguyen Tran
20 papers
Wen Ma
17 papers
Mark Truty
16 papers
RK
Richard Kim
16 papers

Clinical trials

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Principal investigator · Not yet recruiting · Phase 2
Amit Mahipal
2026–2028
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Principal investigator · Recruiting
Case Comprehensive Cancer Center
2024–2026
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Principal investigator · Completed · Phase 2
Mayo Clinic
2019–2021
TAS-102 in Treating Advanced Biliary Tract Cancers
Principal investigator · Completed · Phase 2
Mayo Clinic
2017–2021